医疗器械研发九死一生,终止临床项目的事情时有发生,但公司要付出不小的业绩代价。 8月12日,先瑞达医疗(HK06669,股价6.515港元,市值24.42亿港元)发布业绩预告,称2026年上半年的预计净亏损不超过8090万元,相比上年同期约8860万元的净利润,公司由盈转亏,主要原因是公司终止了一项美国临床试验项目——AcoArt Litos®紫杉醇涂层经皮腔内血管成形术(PTA)球囊导管。 ...
Source Link医疗器械研发九死一生,终止临床项目的事情时有发生,但公司要付出不小的业绩代价。 8月12日,先瑞达医疗(HK06669,股价6.515港元,市值24.42亿港元)发布业绩预告,称2026年上半年的预计净亏损不超过8090万元,相比上年同期约8860万元的净利润,公司由盈转亏,主要原因是公司终止了一项美国临床试验项目——AcoArt Litos®紫杉醇涂层经皮腔内血管成形术(PTA)球囊导管。 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.